ESTRACURE SIGNS LICENSING AGREEMENT FOR USE OF MEDIVAS EXCLUSIVE DRUG DELIVERY TECHNOLOGY

Dr. Marc Lussier, Chief Executive Officer of Estracure, Inc., a subsidiary of Duravest, Inc., a publicly traded holding company (OTC BB: DUVT, XETRA: DUV) and Kenneth Carpenter, President and CEO of San Diego based MediVas LLC, announced today the signing of an agreement for the exclusive use of the MediVas PEA drug delivery technology in conjunction with Estracure's core technology to develop a 17-(beta)-Estradiol drug-eluting stent (DES) to treat patients suffering from coronary heart diseases.

PharmaLive (http://www.pharmalive.com/News/index.cfm?articleid=256321&categoryid=10)